ABSTRACT

Objective: To assess the antibody responses and adverse effects of sinopharm vaccine in pregnant women.
Study Design: A prospective cohort study.
Place and Duration of Study: The study was conducted in the Gynaecology Department of Ibn-e-Siena Hospital Multan, Independent Hospital Faisalabad and Mayo Hospital Lahore from January 2021 to January 2022.
Materials and Methods: A total of 90 women were included in the study who were administered Sinopharm. Three out of ninety (3.3%) women received shots in 1^st trimester, 56/90 (62%) in 2^nd trimester and 31/90 (34%) in third trimester. Enzyme-linked immunosorbent assay (ELISA) was used to measure SARS-CoV-2 receptor binding domain (RBD) specific total antibodies and angiotensin-converting enzyme 2 (ACE2) blocking antibodies. The adverse effects on the mother and fetus were evaluated after the delivery.
Results: The administration of the sinopharm vaccine showed no adverse effects or pregnancy complications such as congenital anomalies, miscarriage, preterm delivery, thrombotic events, fetal death or hypertensive disorders. SARS-CoV-2 specific total antibodies were found in 57/90 (63%) women at the time recruitment (when receiving 1^st dose); thus they were considered to be previously infected.  After the second dose, all women were seroconverted. Significantly high levels of RBD binding antibodies and ACE2 blocking antibodies were observed in previously infected women after administration of the second dose compared to uninfected individuals.
Conclusion: The Sinopharm vaccine showed positive results in pregnant women and induced high seroconversion rates and ACE2 blocking antibodies in second and third  trimesters.

Keywords: ACE2 Blocking Antibodies, Pregnant Women SARS-CoV-2, Receptor Binding Antibodies.

How to cite this: Hamayun Z, Javaid U, Ahmed R, Shehzad K, Gul PI.  Antibody Responses Following Covid-19 Vaccine in Pregnant Women- A Prospective Study. Life and Science. 2022; 3(4): 196-199. doi: http://doi.org/10.37185/LnS.1.1.273